DxM MicroScan WalkAway System
The DxM MicroScan WalkAway system delivers trusted detection of emerging and critical antimicrobial resistance with gold-standard1 MIC accuracy. Designed with ease of use as a focal point, this bacterial identification and antimicrobial susceptibility testing (ID/AST) system provides streamlined workflows and enhanced performance compared to its predecessors.2 The DxM MicroScan WalkAway system continues the legacy of innovation and high-quality products you have trusted for 40 years. Enable your laboratory to optimize patient care while reducing risks, costs and operational burden associated with detecting emerging antimicrobial resistance.
Article Discover the Speed and Accuracy of MALDI-TOF
Explore the history of MALDI-TOF and its applications for advancing antimicrobial stewardship.Read article
Webinar Antibiotic Stewardship: The Basics for U.S. Microbiologists
Learn about the basics of antibiotic stewardship as it applies to U.S. microbiologists. In this webinar, Barbara Zimmer, Ph.D., will explore solutions to the challenges laboratories face in combating emerging antibiotic resistance in today’s laboratory.View on demand
Article ID/AST Test Results Done Right with DxM MicroScan WalkAway System
In the detection of infectious disease, speed and accuracy are key, but pathologists shouldn’t have to choose between the two. Find out how one laboratory is optimizing patient care by rapidly and accurately identifying organisms while testing over 30,000 specimens per year.Read article
1Kalorama United States Market for In Vitro Diagnostic Tests, 2017, pg. 878.
2Reference applicable Procedural Manuals for performance characteristics and limitations. Refer to publications for evaluation of performance with emerging resistance.
3ServiceTrak™ Clinical Executive Summary Report for ID/AST Systems, 2019.
4Bulik CC et al. J Clin Microbiol. 2010 July; 48(7): 2402–2406.
5Anderson KF et al. J Clin Microbiol. 2007 August; 45(8): 2723–2725.
6Woodford N et al. J Clin Microbiol. 2010 August; 48(8): 2999–3002.
7The assessment of clinically significant limitations is based upon a tabulation of CLSI Group A and B test and report recommendations published in the M100 guidance documents (excluding species with natural resistance) and 1st and 2nd drugs of choice published in The Medical Letter‘s Handbook of Antimicrobial Therapy, compared with the related FDA 510K summaries, device manufacturer‘s package inserts and product recall information. M100-S17, 2017.
8ServiceTrak™ Clinical Executive Summary Report for ID/AST Systems, 2016.
WASP is a registered trademark or trademark of Copan Italia SpA.
MALDI Biotyper is the property of Bruker Daltonik GmbH.
Prompt is a registered trademark of 3M.